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18–49 years were 57% less likely (OR 0.43 95% CI 0.41–0.46,
p < 0.0001), to receive antilipidemics than patients 65 years
old. Patients with substantial disease burden (Charlson Index >1)
were 9% more likely to receive antilipidemics (OR 1.09, 95% CI
1.01–1.18, p = 0.024) than those with no or moderate disease
burden (Charlson1). CONCLUSION: Although CHD remains
a leading cause of U.S.mortality irrespective of sex, race/ethnicity,
or age, and antilipidemics beneﬁt patients across these demo-
graphic characteristics, we found that females, Blacks, and
younger (aged 18–50 years) Medicaid patients with dyslipidemia
were signiﬁcantly less likely to receive antilipidemics than their
male, White or older counterparts.
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OBJECTIVES: The purpose of this study was to compare the
survival of patients admitted to different types of hospitals for
their ﬁrst acute myocardial infarction (AMI), and to assess how
the deﬁnition of failure and different variables affect the results.
METHODS: The analysis utilized the Victorian Admitted Epi-
sodes Data Set from 1996–2005, which contains data on all
patients admitted to acute private and public hospitals in the
state of Victoria, Australia. A hazard model was used to model
time to failure, which was deﬁned either as 30-day mortality, or
readmission for subsequent AMI. Hospitals were grouped into
one of ﬁve types and these were included as explanatory
variables. Other control variables, including AMI location,
co-morbidities, treatments, and demographics, were added to the
model one by one in order to determine their effect on survival,
and on the effect of hospital type on survival. RESULTS: The
impact and signiﬁcance of hospital type on survival depended
strongly on the deﬁnition of failure. Large teaching hospitals had
signiﬁcantly higher failure rates than all other hospital types
when failure was deﬁned as readmissions, while this ordering
was almost reversed when failure was deﬁned as 30-day mortal-
ity. Controlling for planned and unplanned treatments did not
signiﬁcantly affect these results. Including indices of socio-
economic status ampliﬁed the effects when failure was deﬁned as
readmissions, but had no signiﬁcant effect otherwise. Location of
AMI was signiﬁcant only when failure was deﬁned as 30-day
mortality, and improved the relative performance of large
regional base and suburban hospitals. All other variables were
generally similar in both models. CONCLUSION: The effect of
hospital type on survival depended strongly on the deﬁnition of
failure and somewhat on the inclusion of certain control vari-
ables. The results suggest that comparing the effects of hospital
type using patient outcomes requires careful consideration.
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OBJECTIVES: To evaluate degree of implementation of the
American and European guidelines related to the treatment as
secondary prevention, in the management of patients with acute
myocardial infarction with ST segment elevation (STEMI).
METHODS: Cross-sectional and multicentric study realized in
cardiology outpatient clinics in Spain. Physicians included con-
secutively outpatients over 18 years with STEMI happened
within 2 previous years. The guidelines of reference were the
American College of Cardiology/American Heart Association
(ACC/AHA 2004) and European Society of Cardiology (ESC
2003). Descriptive statistics and comparison of averages (“t” of
Student and Or of Mann-Whitney) and proportions (Chi-
squared) were realized with SAS package. RESULTS: A total
of 1439 out of 1588 patients were valid for analysis (90.6%).
A total of 80.3% were males, middle age were 62.4 years-
old (STD = 11.8) and the average BMI was of 27.8 Kg/m2
(STD = 3.7). The most frequent concomitant diseases were
hypertension (53.6%) and diabetes mellitus type II (28.5%). The
average of time after STEMI was 9.6 months (STD = 7.2). The
treatments more frequently used were statins (93.6%), aspirin
(93.2%) and beta-blockers (83.5%). The treatments used in
accordance with guidelines were antiaggregants/anticoagulants
(99.7% in both guidelines), statins (94.4% in ACC/AHA and
93.5% in ESC) and beta-blockers (83.5% in both guidelines),
staying in the second term ACE inhibitors/ARBs (78.2% ACC/
AHA and 59.7% ESC) and aldosterone antagonists (19.3%), this
one only recommended by the ACC/AHA. To summarize, 65.3%
(ACC/AHA) and 52.4% (ESC) of the patients were being treated
according guidelines. Regarding lifestyle factors, only 9.2%
(ACC/AHA) and 6.4% of patients followed the overall guide-
lines’ recommendations. CONCLUSION: This study shows a
low implementation of guidelines by Spanish physicians in man-
aging patients with STEMI, with more adherences to ACC/AHA
2004 than ESC 2003 guidelines. Treatment recommendations are
more followed than life-style recommendations. Based on this
study, actions are needed to increase adherence of Guidelines in
Spain.
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OBJECTIVES: Surveys evaluating plasma lipid goal attainment
in CHD patients prior to the updated European guidelines on
CVD prevention (Third Joint Task Force [TJTF]) showed that
hypercholesterolemia is inadequately treated. Limited data
accounts for the reasons behind this. The aim of this survey was
to evaluate the current use and efﬁcacy of lipid lowering drugs
(LLD), and to identify possible patient/physician characteristics
associated with failure to be at the TJTF guideline LDL-C target.
METHODS: An European multi-centre, cross sectional survey in
8 countries including patients on LLD for >3 months (stable
medication >6 weeks). One visit was scheduled for data collec-
tion including fasting lipids analysed by a central laboratory. In
all but 1 country physicians and patients ﬁlled in a questionnaire
about aspects of hypercholesterolemia and treatment. Data was
analysed centrally. Determination of individual LDL-C targets
followed 2003 TJTF guidelines including SCORE tables.
RESULTS: A total of 15,199 patients were recruited (14478
included in the ﬁnal analyses) with the following characteristics:
mean (SD) age 63.2 (11.3) yrs (45% females), waist circumfer-
ence 97.0 (13.3) cm. 62% had a history of hypertension, 18%
were smokers, 32% of the subjects had metabolic syndrome
(MS) according to the NCEPATP III criteria. Reason to prescribe
LLD: 67% primary prevention (PP), 33% secondary prevention
(SP) or familial hypercholesterolemia. 93% of the patients used
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statin mono-therapy. Overall 55% of the patients were at target
(56% of PP and SP patients and 54% of MS patients). Multi-
variate analyses of the patient/physician questionnaire from 7
countries that contributed to the complete dataset showed that
non-adherence to LLD intake was an important determinant for
not reaching LDL-C targets (OR: 0.57; [95% CI, 0.48–0.91]).
CONCLUSION: More than 40% of European patients using
LLD are not on target for LDL-C. Measures to increase adher-
ence may have signiﬁcant impact to reach LDL-C targets.
CARDIOVASCULAR DISEASE—Methods and Concepts
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OBJECTIVES: Clinicians have a strong tendency to round blood
pressure (BP) readings, particularly to the closest multiple of ten,
even when using precise digital devices. This poses a challenge
for classifying patients as controlled in economic evaluations
when values fall on the boundary of the deﬁnition (e.g., 140/
90 mmHg), since including or excluding the boundary values will
over- or under-estimate control rates. We describe a simple
sensitivity analysis to gauge the impact of rounded readings.
METHODS: The method attempts to correct the excess number
of values ending in zero by redistributing these in the 5 mmHg
range around the observed value. Thus, a value of 140 mmHg is
replaced by a new hypothetical measurement drawn randomly
between 135–144 mmHg. The correction is made for 90% of
observations falling on the boundary since 10% would naturally
be expected to end in zero. We illustrate the method with simu-
lated data and validate by comparing the proportion below the
threshold with the true, the rounded and the corrected BPs. The
correction was applied to data from an ongoing study of a
hypertension control education program. RESULTS: A sample of
1000 random systolic BPs was generated with mean 155 and
variance 30; these “true” data were then distorted by rounding
40% of values (as observed in the study). The 30.8% in the true
data that were controlled (<140 mmHg) dropped to 28.6% after
rounding; after the correction, the proportion was 30.9%. In
time-to-control (<140/90 mmHg) analyses of the study data,
34.2% of patients had controlled BP at 6 months based on the
observed data. Replicating the analyses with corrected BPs
yielded an estimate of 41.9%. CONCLUSION: The impact of
rounding should be taken into account in analyses of BP data to
minimize bias in control rates, as well as attenuation of treatment
effect estimates that might result.
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AND COSTS OF MEDICATION, PTCA AND CABGTREATMENT
MODALITY ARE HIGHLY DEPENDENT ONTHE
METHODS USED
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OBJECTIVES: In real life patients are not randomly assigned to
the study groups. Thus, the results of reality may be biased by
confounders and heterogeneity. Unsuitable propensity score esti-
mators (PSEs) and explanatory techniques, which are used to
control for observed confounders, may also bias the results. The
PSEs, popular explanatory analysis techniques and the outcomes
of acute coronary heart disease (ACHD) are assessed here.
METHODS: A total of 171 Finnish ACHD patients underwent
medication, percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass grafting (CABG). In a pro-
spective 3-month period, demographics, coronary angiography
results, costs and 15D-based quality of life were collected.
Various multinomial methods including multinomial logistic
(MLRA), stereotype logistic and nested logistic regression analy-
sis as well as naive Bayes classiﬁer was used to elicit the best PSE
using the patients in the data. Ordinary least squares (OLS) RA
with and without ln-transformations as well as generalized linear
models (GLM) were used for the explanatory RA. Multiple mea-
sures (e.g. probability, likelihood, AIC, BIC, deviance, R2,
RMSE, RESET and link-test) ranked the techniques. ACHD out-
comes were reported using unadjusted, adjusted and PS adjusted
estimation. RESULTS: Generally, the best PSE in this study was
MLRA—one additional marker was the fulﬁllment of indepen-
dence of irrelevant alternatives (IIA). In explanatory analysis,
OLS worked well for the QALY effectiveness estimates, which
ranged -0.053–-0.031 for medication, -0.013–0.009 for PTCA,
and 0.010–0.036 for CABG depending on the use of adjustment/
PSE. The ln-transformed OLS gave the best ﬁt for cost data. The
Duan-smoothed estimates for the maximum cost difference were
4.6% for medication, 0% for PTCA, and 14.1% for CABG
depending on the use of adjustment/PSE. CONCLUSION: The
analyses of different PSEs and explanatory models offer tools to
assess the ﬁtness of the models. Observational studies should be
adjusted, favorably using PSE. Thus, the sensitivity analysis of
PSEs is important.
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OBJECTIVES: To evaluate the performance of statin medica-
tions from a retrospective set of prescription and lab data.
METHODS: A high-risk, hyperlipidemic population from a large
western US integrated health plan was screened to identify
patients with a six-month period of anti-hyperlipidemic absti-
nence prior to an initial statin, with at least one subsequent
LDL-C measurement following a minimum four- month period.
Statin treatment effect was evaluated over a sub-sample of
patients who did not switch or augment. Instead of discarding
observations, a combination selection/treatment regression
model was created. The effect of atorvastatin and typical 3rd tier
statins (atorvastatin and rosuvastatin) on change in LDL-C,
adherence, treatment goal attainment (<100 mg/dL), and titrata-
tion was evaluated using two-step and FIML estimators. Change
in LDL-C was estimated using a bivariate selection rule. For
binary dependent variables, two-step FGLS and FIML (trivariate
selection rule) were used. Concomitant diabetes, hypertension,
age, and gender were exogenous regressors in the outcome equa-
tion. For the decision equations, distance from goal at baseline
was included. Recursive and non-recursive decision equations
were utilized. RESULTS: There were 2724 continuously enrolled
patients meeting the initial inclusion criteria. Atorvastatin
(n = 1119) was associated with an increase (signiﬁcant, p < 0.05,
and insigniﬁcant, depending on the model) in LDL-C relative to
other statins (n = 1605). Atorvastatin was associated with a
higher insigniﬁcant probability of adherence and a higher signiﬁ-
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